cardiogenol B | 671225-38-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: cardiogenol B
• 英文别名: Ethanol, 2-[[2-[(4-phenoxyphenyl)amino]-4-pyrimidinyl]amino]-；2-[[2-(4-phenoxyanilino)pyrimidin-4-yl]amino]ethanol
• CAS: 671225-38-0
• 化学式: C₁₈H₁₈N₄O₂
• 分子量: 322.367
• InChiKey: YERNPLQFPFOPFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  79.3
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  2-(2-氯嘧啶-4-基氨基)乙醇 、 4-氨基二苯醚 以 正丁醇 为溶剂， 以80%的产率得到cardiogenol B
  参考文献：
  名称：

  Small Molecules that Induce Cardiomyogenesis in Embryonic Stem Cells

  摘要：

  A phenotypic cell-based screen of a large combinatorial chemical library led to the identification of a class of diaminopyrimidine compounds (cardiogenol A-D) which can selectively and efficiently induce mouse embryonic stem cells (ESCs) to differentiate into cardiomyocytes. ESC-derived cardiomyocytes were shown to express multiple cardiac muscle markers, including myosin heavy chain, GATA-4, MEF2, and Nkx2.5, and spontaneously form beating regions. Such small molecules will serve as useful chemical probes to study cardiac muscle differentiation and may ultimately facilitate the therapeutic application of ESCs for cardiac repair.

  DOI：

  10.1021/ja038950i

文献信息

• [EN] 2, 4 - DIAMINOPYRIMIDINES AND THEIR USE FOR INDUCING CARDIOMYOGENESIS<br/>[FR] 2, 4 - DIAMINOPYRIMIDINES ET LEUR UTILISATION DESTINEE A INDUIRE LA CARDIOMYOGENESE
  申请人：NOVARTIS AG

  公开号：WO2005068437A1

  公开（公告）日：2005-07-28

  The present invention provides compounds of formula (I) useful for inducing cardiomyogenesis in mammalian cells, particularly embryonic stem cells, in vitro and in vivo.

  本发明提供了一种公式（I）的化合物，用于诱导哺乳动物细胞，特别是胚胎干细胞，在体外和体内进行心肌发生。
• TRIAZINE DERIVATIVES AS DIFFERENTIATION CATALYSTS
  申请人：Mihovilovic Marko

  公开号：US20140234965A1

  公开（公告）日：2014-08-21

  A method of inducing differentiation of mammalian cells into cardiomyocyte-like cells by contacting the mammalian cell with a triazine compound of formula (I), wherein X is independently —NR 4 — or —O—, R 4 is hydrogen or C 1-6 -alkyl; R 1 is hydroxy, C 1-6 -alkyl, C 1-6 -alkoxy, carboxy, C 1-6 -alkoxycarbonyl, halo, cyano, nitro, formyl, amino, C 1-6 -alkylamino, or di-C 1-6 -alkylamino, the C 1-6 -alkyl or -alkoxy residue being optionally substituted with one or more R 5 substituents selected from hydroxy, halo, cyano, and nitro; n is 0 to 5; R 2 is hydrogen, aryl, heteroaryl, or C 1-6 -alkyl, the aryl or heteroaryl residue being optionally substituted with one or more R 1 substituents, and where the C 1-6 -alkyl is optionally further substituted with one or more R 5 substituents; and R 3 is selected from hydrogen, halo, NR 4 R 7 , OR 7 , SR 7 , and R 7 , where the same options apply for R 7 as for R 2 ; with the proviso that the compound of formula (I) is not 3-[(4,6-diphenoxy-1,3,5-triazin-2-yl)amino]benzoic acid.

  一种将哺乳动物细胞诱导分化为类心肌细胞的方法，通过将哺乳动物细胞与式（I）的三嗪化合物接触，其中X独立地是—NR4—或—O—，R4是氢或C1-6-烷基；R1是羟基、C1-6-烷基、C1-6-烷氧基、羧基、C1-6-烷氧羰基、卤素、氰基、硝基、甲酰基、氨基、C1-6-烷基氨基或二C1-6-烷基氨基，其中C1-6-烷基或烷氧基残基可以选用一个或多个R5取代基，所述R5取代基被选择为羟基、卤素、氰基和硝基中的一个或多个；n为0至5；R2是氢、芳基、杂环芳基或C1-6-烷基，其中芳基或杂环芳基残基可以选用一个或多个R1取代基，而C1-6-烷基可以选用一个或多个R5取代基；R3被选择为氢、卤素、NR4R7、OR7、SR7和R7，其中对于R2和R7同样适用相同的选项；但式（I）的化合物不包括3-[(4,6-二苯氧基-1,3,5-三嗪-2-基)氨基]苯甲酸。
• US9611457B2
  申请人：——

  公开号：US9611457B2

  公开（公告）日：2017-04-04
• Small Molecules that Induce Cardiomyogenesis in Embryonic Stem Cells
  作者：Xu Wu、Sheng Ding、Qiang Ding、Nathanael S. Gray、Peter G. Schultz

  DOI：10.1021/ja038950i

  日期：2004.2.1

  A phenotypic cell-based screen of a large combinatorial chemical library led to the identification of a class of diaminopyrimidine compounds (cardiogenol A-D) which can selectively and efficiently induce mouse embryonic stem cells (ESCs) to differentiate into cardiomyocytes. ESC-derived cardiomyocytes were shown to express multiple cardiac muscle markers, including myosin heavy chain, GATA-4, MEF2, and Nkx2.5, and spontaneously form beating regions. Such small molecules will serve as useful chemical probes to study cardiac muscle differentiation and may ultimately facilitate the therapeutic application of ESCs for cardiac repair.